1. Home
  2. AVD vs GBIO Comparison

AVD vs GBIO Comparison

Compare AVD & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Vanguard Corporation ($0.10 Par Value)

AVD

American Vanguard Corporation ($0.10 Par Value)

HOLD

Current Price

$4.29

Market Cap

144.6M

Sector

Industrials

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.47

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVD
GBIO
Founded
1969
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
144.6M
35.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AVD
GBIO
Price
$4.29
$5.47
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$12.00
$10.67
AVG Volume (30 Days)
186.1K
40.1K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$530,073,000.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.28
$3.00
52 Week High
$6.33
$13.00

Technical Indicators

Market Signals
Indicator
AVD
GBIO
Relative Strength Index (RSI) 41.43 51.71
Support Level $4.12 $5.22
Resistance Level $4.48 $5.64
Average True Range (ATR) 0.19 0.25
MACD 0.01 0.05
Stochastic Oscillator 30.36 67.19

Price Performance

Historical Comparison
AVD
GBIO

About AVD American Vanguard Corporation ($0.10 Par Value)

American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: